WEST LAFAYETTE, Ind. (Jan. 22, 2024) – Novilytic, an innovator in molecular recognition technology, is proud to announce an exclusive distribution partnership with Avantor, a global supplier of discovery-to-delivery solutions and the parent company of VWR.
Effective immediately, this strategic partnership will make Novilytic’s Proteometer® platform – including the Proteometer-L, Proteometer-UFT, and the upcoming Proteometer-CV readily accessible to laboratories across the United States, Europe Union, and United Kingdom. Leveraging Avantor’s extensive distribution network, this collaboration represents a shared commitment to driving innovation and efficiency in pharmaceutical research.
“Sample preparation has long been a bottleneck in pharmaceutical research. Every time you touch a sample, you risk compromising it,” said Robert Fitzgerald, Manager of Avantor’s Chromatography Portfolio. “The beauty of Novilytic’s Proteometer is that it removes that step entirely. It’s a groundbreaking innovation developed by Dr. Fred Regnier and his brilliant team, yet it is intuitive enough for anyone to use. The Proteometer is a game-changer, and we are thrilled to bring it to our global customer base.”
By engaging Avantor’s global reach and industry expertise, the partnership ensures that the Proteometer platform will be introduced to a wider range of laboratories, significantly enhancing the efficiency of drug discovery and development processes. Together, Novilytic and Avantor aim to streamline the pipeline for bringing life-saving medicines to market faster, safer, and less expensively, ultimately improving global health outcomes.
“This partnership represents a significant milestone for Novilytic as we scale the impact of our groundbreaking Proteometer platform, said Paul Dreier, CEO of Novilytic. By combining our innovative technology with Avantor’s unmatched distribution network, we are setting a new standard for efficiency and reliability in drug discovery, clone selection, and more. Our shared mission is to eliminate inefficiencies in drug development and positively transform patient outcomes worldwide.”
Novilytic’s products are available through Avantor’s website by searching either our company name or the term Proteometer: Avantor is setting science in motion for a better world | Avantor.
Laboratories worldwide can now benefit from the Proteometer’s unique capabilities, streamlining research and accelerating the path to market for critical therapies.
About Novilytic
Novilytic is a leader in molecular recognition technology. Their patented Proteometer product line is revolutionizing drug development and clone selection by eliminating sample preparation steps that save significant time and money. Their transformational technology fundamentally changes the production of antibody and protein-based medicines by providing near-real-time molecular structure analysis. This ultimately helps bring lifesaving treatments to the market faster. For more information, visit Novilytic.com.
About Avantor
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.
For media inquiries:
Ryan Simpson, Director of Marketing, Novilytic, rsimpson@novilytic.com
###
Comentarios